Provided herein are dosage forms and kits comprising angiotensin II that are suitable for the treatment of low blood pressure. In particular, dosage forms and kits that facilitate the ability to rapidly prepare angiotensin II for IV infusion into a subject.

The present invention relates to compositions, methods and kits for the treatment of fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of cardiac fibrosis. The invention provides a method of treating fibrosis in an individual comprising administering an AT2R selective agonist, thereby treating fibrosis.

A method for producing ACE Inhibitor peptides from a protein source or plasma is disclosed. The method utilizes proteolysis by intestinal, blood-circulating, or membrane-bound proteases. The initial synthesis step could require obtaining a protein source either from a human or animal. A protease is added to either a given plasma protein or plasma and incubated. Following incubation, the protease activity must be quenched using a protease inhibitor to inactivate the protease. After incubation with protease inhibitor, the solution will contain a mixture of bioactive ACE inhibitory peptides and inert peptides. This mixture may be purified to select for the ACE inhibitory peptides through centrifugation. The mixture may also be sterilized to remove any microbial contaminants. The ACE inhibitory peptides can be mixed with protein powders, incorporated into baked good and put into other food products to provide food products with the added benefit of lowering blood pressure.

The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.

A method for treating a patient with a vascular disease condition by improving blood flow is provided. The method may include providing the patient with a vascular disease condition; testing a level of EO in the patient; determining, based on the tested level and a threshold level, that EO up-regulation (or EO down-regulation) would facilitate increased Prostacyclin release; providing a medical composition; and administering the medical composition to the patient. The medical composition may include a first dosage of a GABA-a agonist, a second dosage of an Angiotensin II modulator, and a third dosage of at least one EO-regulating compound. The Angiotensin II modulator may include at least one of an ARB and an ACE Inhibitor, the ARB being an Angiotensin II, type 1 receptor antagonist. The at least one EO-regulating compound may be effective to up-regulate (or down-regulate) EO in blood vessels affected by the vascular disease condition. A medical composition is also provided.

A method for treating a patient with a vascular disease condition by improving blood flow is provided. The method may include providing the patient with a vascular disease condition; testing a level of EO in the patient; determining, based on the tested level and a threshold level, that EO up-regulation (or EO down-regulation) would facilitate increased Prostacyclin release; providing a medical composition; and administering the medical composition to the patient. The medical composition may include a first dosage of a GABA-a agonist, a second dosage of an Angiotensin II modulator, and a third dosage of at least one EO-regulating compound. The Angiotensin II modulator may include at least one of an ARB and an ACE Inhibitor, the ARB being an Angiotensin II, type 1 receptor antagonist. The at least one EO-regulating compound may be effective to up-regulate (or down-regulate) EO in blood vessels affected by the vascular disease condition. A medical composition is also provided.

In the invention is provided a polypeptide comprising at least 75 amino acids and having an amino acid sequence having at least 90%, such as at least 95%, 96%, 97, 98%, or 99%, such as 100% sequence identity (% SI) with human Angiotensin-converting enzyme 2 (ACE2) (SEQ ID NO 1), for use in the treatment of COVID19, SARS, or MERS, characterized in that the polypeptide is administered pulmonary and/or nasally. Further is provided the polypeptide for use in reducing the number of active virus particles being exhaled by a treated subject infected by SARS-CoV-2, SARS-CoV, or Mers-CoV. Also a dry powder or an aerosol comprising the polypeptide.

The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.

A method of treating a viral infection may include administering a pharmaceutical composition including a renin-angiotensin system (RAS) modulator to a subject in need thereof to mitigate a cellular and organic impact of the viral infection. The mitigation may include inhibiting reactive oxygen species, inhibiting cytokine release, upregulating angiotensin-converting enzyme 2 (ACE2), and/or downregulating angiotensin II receptor type 1 (AT1). The renin-angiotensin system modulator may include various combinations of an angiotensin receptor blocker (ARB), angiotensin (1-7), an HMG-CoA reductase inhibitor, an angiotensin-converting-enzyme (ACE) inhibitor, 3,3′-diindolylmethane (DIM), indole-3-carbinol (I3C), and/or pirfenidone (PFD). In addition, at least one of the angiotensin receptor blocker, the angiotensin (1-7), the HMG-CoA reductase inhibitor, the angiotensin-converting-enzyme inhibitor, 3,3′-diindolylmethane, indole-3-carbinol, or pirfenidone may be linked to an antioxidant.

The present invention relates to the cyclic peptides that are agonists of the angiotensin II type 2 receptor (hereinafter the AT2 receptor) useful in the treatment of different types of solid cancer, in particular brain, colon, lung and ovarian cancer. The invention further relates to pharmaceutical compositions containing them and uses thereof for the treatment of cancer.